Ironwood Pharmaceuticals, Inc.

As of June 13, 2025, Ironwood Pharmaceuticals has shifted to a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -67.04%.

As of August 8, 2023, Ironwood Pharmaceuticals is considered overvalued and risky, with a negative price-to-book value of -0.29, an EV to EBITDA ratio of 6.72, and a year-to-date return of -67.04%, significantly underperforming the S&P 500's 12.22%.

As of August 8, 2023, Ironwood Pharmaceuticals is considered overvalued and risky due to its financial metrics, including a high EV to EBITDA of 6.72, negative book value for ROE, and significant underperformance compared to peers and the S&P 500.

As of June 13, 2025, Ironwood Pharmaceuticals, Inc. exhibits a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD and bearish daily moving averages, suggesting a cautious outlook.

As of March 2022, the management team of Ironwood Pharmaceuticals, Inc. includes Ms. Julie McHugh (Independent Chairman), Mr. Mark Mallon (CEO), and several directors: Dr. Mark Currie, Dr. Alexander Denner, Mr. Andrew Dreyfus, Mr. Jon Duane, and Ms. Marla Kessler. They oversee the company's strategic direction and operations.

Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing products for unmet medical needs. As of March 2025, it reported net sales of $41 million and a net loss of $37 million, with a market cap of $102.69 million.

As of Jun 18, Ironwood Pharmaceuticals, Inc. has a market capitalization of 102.69 million and net sales of 317.68 million, with a net profit of -31.41 million over the latest four quarters. Shareholder's funds are at -301.33 million, and total assets are 350.91 million as of Dec 24.